Page 258 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 258
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0793 ESTIMATING THE NUMBER OF CHRONIC HEPATITIS C
PATIENTS IN NEED OF TREATMENT AND PROJECTING
THE DISEASE BURDEN DURING 2015-2030 UNDER THE
INTERFERON-FREE TREATMENT REGIMENS IN GREECE
Vana Sypsa*, Ilias Gountas, Georgios Papatheodoridis, Kyriakos Souliotis,
Homie Razavi, Angelos Hatzakis, Greece
P0796 NEW DIRECT ACTING ANTIVIRALS FOR HEPATITIS C
TREATMENT: FIRST RESULTS IN A REAL-LIFE SETTING IN
FRANCE
Alexandre Pariente, André-Jean Rémy*, Jean-Pierre Arpurt, Isabelle Rosa-
Hézode, Christophe Renou, Ramuntxo Arotcarena, Gilles Macaigne,
Hortensia Lison, François Bourhis, Xavier Causse, Arnaud Pauwels,
Stéphanie de Montigny-Lenhardt, Vincent Jouannaud, Hélène Labadie,
Eric Maringe, Jean-Hatem Salloum, Edmond Gagea, Hervé Hagège,
Bruno Lesgourgues, France
P0797 LATE RELAPSE IN PATIENTS WITH CHRONIC HEPATITIS
C TREATED WITH TRIPLE THERAPY BASED ON FIRST
ePOSTERS GENERATION PROTEASE INHIBITORS
Antonio Madejón*, Míriam Romero, Luz Martín-Carbonero,
Marta Sánchez-Carrillo, Ana I. Gil, Irene Francisco, Javier García-
Samaniego, Spain
P0798 THE COST-EFFECTIVENESS OF SOFOSBUVIR- AND
SIMEPREVIR-BASED THERAPIES FOR HCV GENOTYPE 1
INFECTION
Benjamin P. Linas*, Jake R. Morgan, Mai T. Pho, Jared A. Leff,
Bruce R. Schackman, Sabrina A. Assoumou, Joshua A. Salomon,
Kenneth A. Freedberg, Arthur Y. Kim, The United States
P0799 THE PHARMACOKINETICS OF BECLABUVIR (BMS-
791325) WHEN ADMINISTERED IN COMBINATION WITH
DACLATASVIR AND ASUNAPREVIR IN TREATMENT-NAIVE
PATIENTS WITH OR WITHOUT CIRRHOSIS INFECTED WITH
HCV GENOTYPE 1
Bing He*, Karen Sims, Ellen Chung, Wen-Lin Luo, Janice Pursley,
Megan Wind-Rotolo, Frank LaCreta, Richard Bertz, Malaz AbuTarif,
The United States
258 The International Liver Congress™ 2015 • ILC Programme
P0793 ESTIMATING THE NUMBER OF CHRONIC HEPATITIS C
PATIENTS IN NEED OF TREATMENT AND PROJECTING
THE DISEASE BURDEN DURING 2015-2030 UNDER THE
INTERFERON-FREE TREATMENT REGIMENS IN GREECE
Vana Sypsa*, Ilias Gountas, Georgios Papatheodoridis, Kyriakos Souliotis,
Homie Razavi, Angelos Hatzakis, Greece
P0796 NEW DIRECT ACTING ANTIVIRALS FOR HEPATITIS C
TREATMENT: FIRST RESULTS IN A REAL-LIFE SETTING IN
FRANCE
Alexandre Pariente, André-Jean Rémy*, Jean-Pierre Arpurt, Isabelle Rosa-
Hézode, Christophe Renou, Ramuntxo Arotcarena, Gilles Macaigne,
Hortensia Lison, François Bourhis, Xavier Causse, Arnaud Pauwels,
Stéphanie de Montigny-Lenhardt, Vincent Jouannaud, Hélène Labadie,
Eric Maringe, Jean-Hatem Salloum, Edmond Gagea, Hervé Hagège,
Bruno Lesgourgues, France
P0797 LATE RELAPSE IN PATIENTS WITH CHRONIC HEPATITIS
C TREATED WITH TRIPLE THERAPY BASED ON FIRST
ePOSTERS GENERATION PROTEASE INHIBITORS
Antonio Madejón*, Míriam Romero, Luz Martín-Carbonero,
Marta Sánchez-Carrillo, Ana I. Gil, Irene Francisco, Javier García-
Samaniego, Spain
P0798 THE COST-EFFECTIVENESS OF SOFOSBUVIR- AND
SIMEPREVIR-BASED THERAPIES FOR HCV GENOTYPE 1
INFECTION
Benjamin P. Linas*, Jake R. Morgan, Mai T. Pho, Jared A. Leff,
Bruce R. Schackman, Sabrina A. Assoumou, Joshua A. Salomon,
Kenneth A. Freedberg, Arthur Y. Kim, The United States
P0799 THE PHARMACOKINETICS OF BECLABUVIR (BMS-
791325) WHEN ADMINISTERED IN COMBINATION WITH
DACLATASVIR AND ASUNAPREVIR IN TREATMENT-NAIVE
PATIENTS WITH OR WITHOUT CIRRHOSIS INFECTED WITH
HCV GENOTYPE 1
Bing He*, Karen Sims, Ellen Chung, Wen-Lin Luo, Janice Pursley,
Megan Wind-Rotolo, Frank LaCreta, Richard Bertz, Malaz AbuTarif,
The United States
258 The International Liver Congress™ 2015 • ILC Programme
